Catalyzing transcriptomics research in cardiovascular disease

The CardioRNA COST action CA17129

EU-CardioRNA COST Action (CA17129)

Research output: Contribution to journalArticle

Abstract

Cardiovascular disease (CVD) remains the leading cause of death worldwide and, despite continuous advances, better diagnostic and prognostic tools, as well as therapy, are needed. The human transcriptome, which is the set of all RNA produced in a cell, is much more complex than previously thought and the lack of dialogue between researchers and industrials and consensus on guidelines to generate data make it harder to compare and reproduce results. This European Cooperation in Science and Technology (COST) Action aims to accelerate the understanding of transcriptomics in CVD and further the translation of experimental data into usable applications to improve personalized medicine in this field by creating an interdisciplinary network. It aims to provide opportunities for collaboration between stakeholders from complementary backgrounds, allowing the functions of different RNAs and their interactions to be more rapidly deciphered in the cardiovascular context for translation into the clinic, thus fostering personalized medicine and meeting a current public health challenge. Thus, this Action will advance studies on cardiovascular transcriptomics, generate innovative projects, and consolidate the leadership of European research groups in the field. COST (European Cooperation in Science and Technology) is a funding organization for research and innovation networks (www.cost.eu).

Original languageEnglish
Article number31
JournalNon-coding RNA
Volume5
Issue number2
DOIs
Publication statusPublished - 1 Jan 2019

Fingerprint

Precision Medicine
Medicine
Cardiovascular Diseases
RNA
Technology
Foster Home Care
Public health
Transcriptome
Research
Cause of Death
Consensus
Public Health
Innovation
Research Personnel
Organizations
Guidelines
Therapeutics

Keywords

  • Best practices and guidelines
  • Cardiovascular disease
  • Personalized medicine
  • Transcriptomics
  • Translational research

Cite this

@article{7653b97fa77243668c52904d034a9574,
title = "Catalyzing transcriptomics research in cardiovascular disease: The CardioRNA COST action CA17129",
abstract = "Cardiovascular disease (CVD) remains the leading cause of death worldwide and, despite continuous advances, better diagnostic and prognostic tools, as well as therapy, are needed. The human transcriptome, which is the set of all RNA produced in a cell, is much more complex than previously thought and the lack of dialogue between researchers and industrials and consensus on guidelines to generate data make it harder to compare and reproduce results. This European Cooperation in Science and Technology (COST) Action aims to accelerate the understanding of transcriptomics in CVD and further the translation of experimental data into usable applications to improve personalized medicine in this field by creating an interdisciplinary network. It aims to provide opportunities for collaboration between stakeholders from complementary backgrounds, allowing the functions of different RNAs and their interactions to be more rapidly deciphered in the cardiovascular context for translation into the clinic, thus fostering personalized medicine and meeting a current public health challenge. Thus, this Action will advance studies on cardiovascular transcriptomics, generate innovative projects, and consolidate the leadership of European research groups in the field. COST (European Cooperation in Science and Technology) is a funding organization for research and innovation networks (www.cost.eu).",
keywords = "Best practices and guidelines, Cardiovascular disease, Personalized medicine, Transcriptomics, Translational research",
author = "{EU-CardioRNA COST Action (CA17129)} and {da Costa Gomes}, {Clarissa Pedrosa} and Bence {\'A}gg and Andrejaana Andova and Serdal Arslan and Andrew Baker and Monika Bartekov{\'a} and Dimitris Beis and Fay Betsou and Wettinger, {Stephanie Bezzina} and Branko Bugarski and Gianluigi Condorelli and {da Silva}, {Gustavo Jos{\'e} Justo} and Sabrina Danilin and {de Gonzalo-Calvo}, David and Alfonso Buil and Maria Carmo-Fonseca and Enguita, {Francisco J.} and Kyriacos Felekkis and Peter Ferdinandy and Mariann Gy{\"o}ngy{\"o}si and Matthias Hackl and Kanita Karaduzovic-Hadziabdic and Jan Hellemans and Stephane Heymans and Mark{\'e}ta Hlavackova and Hoydal, {Morten Andre} and Aleksandra Jankovic and Amela Jusic and Dimitris Kardassis and Risto Kerkel{\"a} and Kuster, {Gabriela M.} and P{\"a}ivi Lakkisto and Przemyslaw Leszek and Mitja Lustrek and Lars Maegdefessel and Fabio Martelli and Susana Novella and Timothy O'Brien and Christos Papaneophytou and Thierry Pedrazzini and Florence Pinet and Octavian Popescu and Ines Potočnjak and Emma Robinson and Shlomo Sasson and Markus Scholz and Maya Simionescu and Monika Stoll and Varga, {Zoltan V.} and Manlio Vinciguerra",
year = "2019",
month = "1",
day = "1",
doi = "10.3390/NCRNA5020031",
language = "English",
volume = "5",
journal = "Non-coding RNA",
issn = "2311-553X",
publisher = "MDPI AG",
number = "2",

}

Catalyzing transcriptomics research in cardiovascular disease : The CardioRNA COST action CA17129. / EU-CardioRNA COST Action (CA17129).

In: Non-coding RNA, Vol. 5, No. 2, 31, 01.01.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Catalyzing transcriptomics research in cardiovascular disease

T2 - The CardioRNA COST action CA17129

AU - EU-CardioRNA COST Action (CA17129)

AU - da Costa Gomes, Clarissa Pedrosa

AU - Ágg, Bence

AU - Andova, Andrejaana

AU - Arslan, Serdal

AU - Baker, Andrew

AU - Barteková, Monika

AU - Beis, Dimitris

AU - Betsou, Fay

AU - Wettinger, Stephanie Bezzina

AU - Bugarski, Branko

AU - Condorelli, Gianluigi

AU - da Silva, Gustavo José Justo

AU - Danilin, Sabrina

AU - de Gonzalo-Calvo, David

AU - Buil, Alfonso

AU - Carmo-Fonseca, Maria

AU - Enguita, Francisco J.

AU - Felekkis, Kyriacos

AU - Ferdinandy, Peter

AU - Gyöngyösi, Mariann

AU - Hackl, Matthias

AU - Karaduzovic-Hadziabdic, Kanita

AU - Hellemans, Jan

AU - Heymans, Stephane

AU - Hlavackova, Markéta

AU - Hoydal, Morten Andre

AU - Jankovic, Aleksandra

AU - Jusic, Amela

AU - Kardassis, Dimitris

AU - Kerkelä, Risto

AU - Kuster, Gabriela M.

AU - Lakkisto, Päivi

AU - Leszek, Przemyslaw

AU - Lustrek, Mitja

AU - Maegdefessel, Lars

AU - Martelli, Fabio

AU - Novella, Susana

AU - O'Brien, Timothy

AU - Papaneophytou, Christos

AU - Pedrazzini, Thierry

AU - Pinet, Florence

AU - Popescu, Octavian

AU - Potočnjak, Ines

AU - Robinson, Emma

AU - Sasson, Shlomo

AU - Scholz, Markus

AU - Simionescu, Maya

AU - Stoll, Monika

AU - Varga, Zoltan V.

AU - Vinciguerra, Manlio

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Cardiovascular disease (CVD) remains the leading cause of death worldwide and, despite continuous advances, better diagnostic and prognostic tools, as well as therapy, are needed. The human transcriptome, which is the set of all RNA produced in a cell, is much more complex than previously thought and the lack of dialogue between researchers and industrials and consensus on guidelines to generate data make it harder to compare and reproduce results. This European Cooperation in Science and Technology (COST) Action aims to accelerate the understanding of transcriptomics in CVD and further the translation of experimental data into usable applications to improve personalized medicine in this field by creating an interdisciplinary network. It aims to provide opportunities for collaboration between stakeholders from complementary backgrounds, allowing the functions of different RNAs and their interactions to be more rapidly deciphered in the cardiovascular context for translation into the clinic, thus fostering personalized medicine and meeting a current public health challenge. Thus, this Action will advance studies on cardiovascular transcriptomics, generate innovative projects, and consolidate the leadership of European research groups in the field. COST (European Cooperation in Science and Technology) is a funding organization for research and innovation networks (www.cost.eu).

AB - Cardiovascular disease (CVD) remains the leading cause of death worldwide and, despite continuous advances, better diagnostic and prognostic tools, as well as therapy, are needed. The human transcriptome, which is the set of all RNA produced in a cell, is much more complex than previously thought and the lack of dialogue between researchers and industrials and consensus on guidelines to generate data make it harder to compare and reproduce results. This European Cooperation in Science and Technology (COST) Action aims to accelerate the understanding of transcriptomics in CVD and further the translation of experimental data into usable applications to improve personalized medicine in this field by creating an interdisciplinary network. It aims to provide opportunities for collaboration between stakeholders from complementary backgrounds, allowing the functions of different RNAs and their interactions to be more rapidly deciphered in the cardiovascular context for translation into the clinic, thus fostering personalized medicine and meeting a current public health challenge. Thus, this Action will advance studies on cardiovascular transcriptomics, generate innovative projects, and consolidate the leadership of European research groups in the field. COST (European Cooperation in Science and Technology) is a funding organization for research and innovation networks (www.cost.eu).

KW - Best practices and guidelines

KW - Cardiovascular disease

KW - Personalized medicine

KW - Transcriptomics

KW - Translational research

UR - http://www.scopus.com/inward/record.url?scp=85069910260&partnerID=8YFLogxK

U2 - 10.3390/NCRNA5020031

DO - 10.3390/NCRNA5020031

M3 - Article

VL - 5

JO - Non-coding RNA

JF - Non-coding RNA

SN - 2311-553X

IS - 2

M1 - 31

ER -